Avience Biomedicals IPO GMP Today, Price & Details
Avience Biomedicals IPO GMP Today, Price Band, Subscription Status, Allotment & Listing Details
About Avience Biomedicals
Avience Biomedicals operates in the medical and healthcare products space, a segment that benefits from steady, non-discretionary demand and rising healthcare spending in India. As a small, specialised manufacturer, it sits in a niche where regulatory approvals and quality standards create barriers to entry. The IPO was an SME offering on the NSE, sized at ₹30.24 Cr and priced at ₹196–208 per share with a face value of ₹10.
For its size, the financials are striking. Revenue of ₹41.84 Cr and net profit of ₹5.74 Cr come with an excellent EBITDA margin of 25.22% and an exceptional RONW of 49.89%, alongside a 24.88% ROCE. Those are high-quality numbers for a company this small.
This was a 100% fresh issue, so the entire ₹30.24 Cr goes into the business. For a small, fast-growing medical-products maker, that capital can meaningfully expand capacity and reach.
Avience Biomedicals IPO — Investment Analysis
At the upper band of ₹208, Avience was valued at 15.66x earnings on an EPS of ₹12.52 — a reasonable multiple given the exceptional return profile. For a business generating a 49.89% RONW, that pricing looked undemanding.
The financial quality is the standout. A 25.22% EBITDA margin and near-50% RONW are outstanding, and while revenue of ₹41.84 Cr is small, the profitability per rupee of capital is remarkable. The healthcare niche also lends the business defensive, non-discretionary demand.
The risks are those of scale and concentration. At this size, growth can be lumpy, a few clients or products may drive most revenue, and sustaining a 49.89% RONW as the company scales is a tall order. Regulatory compliance in medical products is another ongoing demand.
The market response was euphoric. The issue was subscribed 196.77x, and the stock delivered a blockbuster listing, opening at ₹395.20 against the ₹208 issue price — a gain of roughly 90% — before firming to ₹414.95. Our IPO profit calculator can size those returns. Investors should consult a SEBI-registered financial advisor before making investment decisions.
Disclaimer: This analysis is auto-generated from publicly available financial data and should not be considered investment advice. Always consult a SEBI-registered financial advisor before making investment decisions.
Avience Biomedicals IPO — Pros & Cons
Strengths
- An exceptional RONW of 49.89% paired with a 25.22% EBITDA margin — outstanding profitability for a company of this size.
- A reasonable valuation at 15.66x earnings given the return profile, leaving room for the strong listing that followed.
- A defensive healthcare niche with non-discretionary demand and regulatory barriers to entry.
- A 100% fresh issue means the full ₹30.24 Cr funds capacity and growth.
- A blockbuster debut — a 196.77x subscription and a roughly 90% listing gain to ₹395.20.
Risks
- Very small scale, with revenue of just ₹41.84 Cr, makes growth lumpy and the business more fragile than larger peers.
- Sustaining a near-50% RONW as the company scales is extremely difficult — mean reversion is a real risk.
- Client or product concentration is common at this size and could hit revenue if a key account is lost.
- The roughly 90% listing pop leaves the post-listing price richly valued, with less room for further quick upside.
- SME liquidity is thin, so the stock can swing sharply on modest volumes.
Avience Biomedicals IPO Details
| Company Name | Avience Biomedicals |
|---|---|
| IPO Type | SME |
| Exchange | NSE |
| Price Band | ₹196 - ₹208 |
| Face Value | ₹10 per share |
| Lot Size | 600 shares |
| Min Investment | ₹124,800 |
| Total Issue Size | ₹30.24 Cr |
|---|---|
| Fresh Issue | ₹30.24 Cr |
| Registrar | Skyline Financial Services Pvt.Ltd. |
| Lead Manager | List of Issues managed, Fintellectual Corporate Advisors Pvt.Ltd. |
| IPO Status | Listed |
Avience Biomedicals IPO Dates
Avience Biomedicals IPO Subscription Status
Day-wise Subscription Trend
| Date | Retail | NII/HNI | QIB | Total |
|---|---|---|---|---|
| 22 Jun 2026 | 401.21x | 597.62x | 196.77x | 385.33x |
| 19 Jun 2026 | 58.02x | 66.63x | 0.03x | 43.38x |
| 18 Jun 2026 | 15.23x | 13.43x | 0.00x | 10.51x |
Avience Biomedicals IPO Listing Performance
Avience Biomedicals IPO listed on NSE on 25 Jun 2026 at ₹395, a premium of 90% over the issue price of ₹208. Investors who received allotment made a profit of ₹112,320 per lot (600 shares) on listing day.
Avience Biomedicals IPO — Key Highlights
- Medical-products SME, NSE IPO of ₹30.24 Cr.
- Exceptional RONW of 49.89% and 25.22% EBITDA margin.
- Subscribed 196.77x overall.
- Blockbuster listing — opened at ₹395.20 versus ₹208 (+90%).
- A 100% fresh issue of ₹30.24 Cr.
- Reasonably valued at 15.66x earnings on an EPS of ₹12.52.
Avience Biomedicals Financial Performance
| Metric (₹ Cr) | FY 2024 | FY 2025 | 10M FY 2026 |
|---|---|---|---|
| Revenue | 23.96 | 45.24 | 41.84 |
| Expenses | 21.42 | 36.17 | 34.06 |
| Net Income (PAT) | 2.14 | 7.23 | 5.74 |
| Margin (%) | 8.93% | 15.98% | 13.72% |
Avience Biomedicals IPO Valuations & Key Metrics
Valuation Ratios
| EPS | ₹12.52 |
|---|---|
| P/E Ratio | 15.66x |
| NAV | ₹56.50 |
| Debt/Equity | 0.970 |
Return Metrics
| RONW (%) | 49.89% |
|---|---|
| ROCE (%) | 24.88% |
| EBITDA Margin | 25.22% |
| Employees | 75 |
Avience Biomedicals IPO Reservation / Allocation
Avience Biomedicals IPO Lead Manager & Registrar
Book Running Lead Manager
List of Issues managed, Fintellectual Corporate Advisors Pvt.Ltd.
IPO Registrar
Skyline Financial Services Pvt.Ltd.
Avience Biomedicals IPO — Frequently Asked Questions
What is Avience Biomedicals IPO GMP today?
As of today, the Grey Market Premium (GMP) for Avience Biomedicals IPO is ₹145 per share, indicating a potential listing premium of 69.7% above the issue price of ₹208.
What is the price band and lot size of Avience Biomedicals IPO?
Avience Biomedicals IPO has a price band of ₹196 to ₹208 per equity share with a face value of ₹10. The minimum lot size is 600 shares, requiring a minimum investment of ₹124,800 at the upper band.
What are the important dates for Avience Biomedicals IPO?
Avience Biomedicals IPO opens for subscription on 18 Jun 2026 and closes on 22 Jun 2026. Allotment is expected on 23 Jun 2026. The shares are expected to list on NSE on 25 Jun 2026.
What is the investor category allocation in Avience Biomedicals IPO?
The shares are reserved as follows — Qualified Institutional Buyers (QIB): 49.83%, Non-Institutional Investors (NII/HNI): 15.09%, and Retail Individual Investors: 35.08%.
How can I apply for Avience Biomedicals IPO?
You can apply for Avience Biomedicals IPO through your bank's net banking ASBA facility or via UPI-based application through any stockbroker platform. Ensure you have sufficient funds in your bank account as the amount will be blocked until allotment. The registrar for this IPO is Skyline Financial Services Pvt.Ltd..
What is the subscription status of Avience Biomedicals IPO?
Avience Biomedicals IPO has been subscribed 196.77 times overall. Retail category: 0.00x, NII/HNI: 0.00x, QIB: 196.77x.
What was Avience Biomedicals IPO's price band and lot size?
Avience Biomedicals was priced at ₹196 to ₹208 per share, with a lot of 600 shares — a per-lot value of about ₹1.25 lakh at the upper band. The face value was ₹10.
How did Avience Biomedicals perform on listing?
Spectacularly — after a 196.77x subscription, the stock opened at ₹395.20 against its ₹208 issue price, a gain of about 90%, and firmed to ₹414.95.
How strong are Avience Biomedicals' financials?
Very strong for its size: revenue of ₹41.84 Cr, a 25.22% EBITDA margin, and an exceptional RONW of 49.89% — though the small scale means growth can be lumpy.
What are the key risks in Avience Biomedicals IPO?
Its small scale (₹41.84 Cr revenue), the difficulty of sustaining a near-50% RONW as it grows, and thin SME liquidity are the main risks.